RBC Capital analyst Brian Abrahams lowered the firm’s price target on Incyte (INCY) to $74 from $80 and keeps a Sector Perform rating on the shares. The analyst firm the company’s announced and “disappointing” enrollment pause for MRGPRX2 on preclinical tox findings, noting that while the asset was early and “always higher risk”, the large potential market opportunity in CSU/CInDU and proximity to proof-of-concept data had made it one of Incyte’s higher-profile pipeline programs with the potential to be “transformative if successful”, the analyst tells investors in a research note. There is uncertainty on next steps and readout cadence for the program, pending clarity from FDA, RBC adds.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Closing Bell Movers: Super Micro up 28% on compliance update
- Incyte down 9% at $70 after update on MRGPRX2, MRGPRX4 programs
- Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP
- Incyte price target raised to $80 from $72 at RBC Capital
- Bank of America Turns Bullish on These 2 Lesser-Known Stocks